Trial reportThe lancet. Psychiatry2016
Effect of antidepressant treatment on cognitive impairments associated with depression: a randomised longitudinal study.
Trial report in The lancet. Psychiatry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00693849 (International Study to Predict Optimised Treatment - in Depression), which is not on this map. Cited by 123 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
International Study to Predict Optimised Treatment - in Depression
Who cites it
123 citing papers in PubMed, 6 syntheses or guidelines pooled it, 240 citations in OpenAlex.
- Augmentation Therapy With Serotonin 5-HTNeuropsychopharmacology reports · 2025Pooled it
- Change in Cognitive Function over the Course of Major Depressive Disorder: A Systematic Review and Meta-analysis.Neuropsychology review · 2025Pooled it
- Depression and episodic memory across the adult lifespan: A meta-analytic review.Psychological bulletin · 2021Pooled it
- Physical exercise improves quality of life, depressive symptoms, and cognition across chronic brain disorders: a transdiagnostic systematic review and meta-analysis of randomized controlled trials.Journal of neurology · 2021Pooled it
- Cognitive Performance in First-Degree Relatives of Individuals With vs Without Major Depressive Disorder: A Meta-analysis.JAMA psychiatry · 2019Pooled it
- Increased Risk of Dementia in Patients with Antidepressants: A Meta-Analysis of Observational Studies.Behavioural neurology · 2018Pooled it
- Safety, tolerability, and preliminary efficacy of seltorexant versus quetiapine extended release as adjunctive therapy in major depressive disorder: a randomized, flexible-dose, 6-month, parallel-group, exploratory study.The international journal of neuropsychopharmacology · 2026Trial
- The Effect of N-Acetylcysteine (NAC) on Neurometabolites and Cognitive Function in Adults With Alcohol Use Disorder: A Preliminary Randomized Controlled Trial.Neuropsychopharmacology reports · 2025Trial
- Real-World Effects of Home-Based Transcranial Direct Current Stimulation in Depression: A Randomized Controlled Trial of 3-Week Versus 6-Week Protocols.Brain and behavior · 2025Trial
- Model-based planning is unaffected by ketamine, antidepressant and internet delivered cognitive behavioural therapy treatments in depression.Translational psychiatry · 2025Trial
- A Randomized Controlled Study of Efficacy and Cognitive Function Improvement of Vortioxetine and Escitalopram in Patients with Depression in Chinese Han Nationality.Neuropsychiatric disease and treatment · 2024Trial
- 5-HTBiological psychiatry. Cognitive neuroscience and neuroimaging · 2023Trial
- A Cognitive Biotype of Depression and Symptoms, Behavior Measures, Neural Circuits, and Differential Treatment Outcomes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.JAMA network open · 2023Trial
- Evaluating cognitive disturbances as treatment target and predictor of antidepressant action in major depressive disorder: A NeuroPharm study.Translational psychiatry · 2022Trial
- Slowed Processing Speed Disrupts Patient Expectancy in Late Life Depression.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2021Trial
- Trial
- Trial
- Connectivity of the Cognitive Control Network During Response Inhibition as a Predictive and Response Biomarker in Major Depression: Evidence From a Randomized Clinical Trial.Biological psychiatry · 2020Trial
- Neurocognitive Effects of Combined Electroconvulsive Therapy (ECT) and Venlafaxine in Geriatric Depression: Phase 1 of the PRIDE Study.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2020Trial
- RETRACTED: Effects of L-DOPA Monotherapy on Psychomotor Speed and [Biological psychiatry · 2019Trial
63 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundAntidepressant treatment failure is a common problem worldwide. In this study, we assess whether or not an important aspect of depression, cognitive impairment, is untreated by antidepressants by studying the effect of acute antidepressant treatment on a range of cognitive domains.
methodsIn this randomised longitudinal study, which is part of the International Study to Predict Optimized Treatment in Depression (iSPOT-D) trial, we assessed the effects of acute antidepressant treatment in a large patient population, across clinical remission outcomes, on a range of cognitive domains: attention, response inhibition, executive function during visuospatial navigation, cognitive flexibility, verbal memory, working memory, decision speed, information processing speed, and psychomotor response speed. We enrolled patients from primary or specialty care clinics in a multicentre, international, open-label, randomised, prospective trial. Eligible patients (aged 18-65 years) were previously untreated or were willing to undergo a 1-week medication washout before the study start, and could not have had inadequate response to study medications in the past. We enrolled a large population of medication-free (ie, untreated) outpatients in a depressive episode and assessed them for cognitive function at enrolment (pre-treatment), and again after 8 weeks of treatment with one of three antidepressant drugs (escitalopram, sertraline, or venlafaxine extended-release). Patients were randomly assigned (1:1:1) to one of the three antidepressants using a blocked randomisation procedure (block size of 12). As a comparison group, we also simultaneously enrolled matched healthy participants. Healthy participants received no medication or intervention, but were assessed for change in cognitive and clinical measures during the same interval and testing protocol. Therefore, this group acts as a test-retest control for the primary outcome measure examined in this study, change in cognitive measures over 8 weeks of treatment in depressed patients. This study is registered with ClinicalTrials.gov, number NCT00693849.
findingsBetween Dec 8, 2008, and Sept 30, 2011, we enrolled 1008 eligible people into the study. Impairment in five domains-attention, response inhibition, verbal memory, decision speed, and information processing-showed no relative improvement with acute treatment (controlling for time or repeated testing), irrespective of antidepressant treatment group, even in patients whose depression remitted acutely according to clinical measures. Broader cognitive impairment was associated with greater illness chronicity (earlier illness onset) but not with symptom severity or previous antidepressant failures.
interpretationDepression is associated with impairments in higher-order cognitive functions and information processing, which persist independently of clinical symptom change with treatment. We recorded no difference between the three antidepressants tested, with none showing efficacy for these impairments. Although the 8-week treatment period limits interpretation to acute treatment effects, it does highlight cognitive impairment as an untargeted contributor to incomplete treatment success.
fundingBrain Resource Company Operations Pty Ltd and NIH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.